Marina Díaz‐Beyá

2.1k total citations · 1 hit paper
38 papers, 842 citations indexed

About

Marina Díaz‐Beyá is a scholar working on Hematology, Molecular Biology and Genetics. According to data from OpenAlex, Marina Díaz‐Beyá has authored 38 papers receiving a total of 842 indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Hematology, 17 papers in Molecular Biology and 11 papers in Genetics. Recurrent topics in Marina Díaz‐Beyá's work include Acute Myeloid Leukemia Research (24 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (9 papers) and Histone Deacetylase Inhibitors Research (6 papers). Marina Díaz‐Beyá is often cited by papers focused on Acute Myeloid Leukemia Research (24 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (9 papers) and Histone Deacetylase Inhibitors Research (6 papers). Marina Díaz‐Beyá collaborates with scholars based in Spain, Switzerland and Belgium. Marina Díaz‐Beyá's co-authors include Jordi Esteve, Carmen Martı́nez, Enric Carreras, Montserrat Rovira, Anna Gayà, Francesc Fernández‐Avilés, Laura Rosiñol, Marta Pratcorona, Xavier Calvo and Alejandra Martínez‐Trillos and has published in prestigious journals such as Blood, PLoS ONE and Scientific Reports.

In The Last Decade

Marina Díaz‐Beyá

34 papers receiving 829 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

CAR-T cell therapy for cancer: current challenges and future directions

2025 40 citations Marina Díaz‐Beyá, Álvaro Urbano-Ispizúa et al. profile →

Peers

Countries citing papers authored by Marina Díaz‐Beyá

Since Specialization

Citations

This map shows the geographic impact of Marina Díaz‐Beyá's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Marina Díaz‐Beyá with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Marina Díaz‐Beyá more than expected).

Fields of papers citing papers by Marina Díaz‐Beyá

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Marina Díaz‐Beyá. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Marina Díaz‐Beyá. The network helps show where Marina Díaz‐Beyá may publish in the future.

Co-authorship network of co-authors of Marina Díaz‐Beyá

This figure shows the co-authorship network connecting the top 25 collaborators of Marina Díaz‐Beyá. A scholar is included among the top collaborators of Marina Díaz‐Beyá based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Marina Díaz‐Beyá. Marina Díaz‐Beyá is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Rapid Screening and Monitoring of UBA1 Mutations in VEXAS Syndrome 2025 ·Journal of Molecular Diagnostics ·(unknown), Elvira Mora, Rafael Hernani, José Cervera, (unknown), (unknown), Esperanza Such, Marisa Calabuig, Rosario Abellán, Marina Díaz‐Beyá, Juan Carlos Hernández‐Boluda, Carlos Solano, Eva Villamón, Mar Tormo	0
2	At-Home Care Program for Acute Myeloid Leukemia Induction Phase in Patients Treated with Venetoclax-Based Low-Intensity Regimens 2024 ·Cancers ·(unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Álex Bataller, Francesca Guijarro, (unknown), (unknown), (unknown), (unknown), (unknown), Luis Gerardo Rodríguez‐Lobato, (unknown), Marina Díaz‐Beyá, Jordi Esteve, Francesc Fernández‐Avilés	1
3	Evaluation of European LeukemiaNet 2022 risk classification in patients undergoing allogeneic haematopoietic stem cell transplantation for acute myeloid leukaemia: Identification of a very poor prognosis genetic group 2024 ·British Journal of Haematology ·(unknown), (unknown), (unknown), Francesca Guijarro, Mònica López‐Guerra, (unknown), (unknown), (unknown), (unknown), (unknown), Laura Rosiñol, Enric Carreras, Álvaro Urbano-Ispizúa, Francesc Fernández‐Avilés, Carmen Martı́nez, María Suárez‐Lledó, Marina Díaz‐Beyá, Montserrat Rovira, María Queralt Salas, Jordi Esteve	5
4	Outcomes of older adults undergoing allogeneic hematopoietic cell transplantation with post‐transplant cyclophosphamide based prophylaxis 2024 ·European Journal Of Haematology ·(unknown), (unknown), María Suárez‐Lledó, (unknown), Cristina Moreno, Joan Cid, Miquel Lozano, Alexandra Pedraza, (unknown), (unknown), (unknown), Marina Díaz‐Beyá, Laura Rosiñol, Jordi Esteve, Enric Carreras, Francesc Fernández‐Avilés, Carmen Martı́nez, Montserrat Rovira, María Queralt Salas	0
5	Whole Exome Sequencing of Intermediate-Risk Acute Myeloid Leukemia without Recurrent Genetic Abnormalities Offers Deeper Insights into New Diagnostic Classifications 2024 ·International Journal of Molecular Sciences ·Francesca Guijarro, (unknown), (unknown), (unknown), (unknown), (unknown), Irene López‐Oreja, Jordi Morata, Mònica López‐Guerra, Cristina López, Sı́lvia Beà, Dolors Costa, Dolors Colomer, Marina Díaz‐Beyá, Marı́a Rozman, (unknown)	1
6	Clinical management of patients diagnosed with acute myeloid leukemia treated with venetoclax in combination with hypomethylating agents after achieving a response: a real-life study 2024 ·Annals of Hematology ·(unknown), (unknown), (unknown), (unknown), (unknown), Francesca Guijarro, (unknown), (unknown), (unknown), Isabel Hernández, (unknown), (unknown), (unknown), Francesc Fernández‐Avilés, Marina Díaz‐Beyá, Jordi Esteve	3
7	A novel ETV6::FGFR1 fusion gene in a myeloid/lymphoid neoplasm with FGFR1 rearrangement sensitive to specific FGFR1-2-3 inhibition 2023 ·Leukemia & lymphoma ·(unknown), (unknown), Mònica López‐Guerra, Eva Villamón, Francesca Guijarro, (unknown), (unknown), (unknown), Alberto Álvarez‐Larrán, Juan Carlos Hernández‐Boluda, Montserrat Rovira, Dolors Colomer, Marina Díaz‐Beyá, Marı́a Rozman, (unknown)	0
8	Mutational Profile Enables the Identification of a High-Risk Subgroup in Myelodysplastic Syndromes with Isolated Trisomy 8 2023 ·Cancers ·(unknown), (unknown), (unknown), Esperanza Such, Montserrat Arnán, Françesc Solé, Marina Díaz‐Beyá, María Díez‐Campelo, Mónica Del Rey, Teresa González, Jesús María Hernández‐Rivas	5
9	Characteristics and long‐term outcome in a large series of chronic myelomonocytic leukaemia patients including 104 formerly referred to as oligomonocytic 2023 ·British Journal of Haematology ·(unknown), Helena Pomares, (unknown), Francesca Guijarro, (unknown), (unknown), (unknown), (unknown), Mònica López‐Guerra, (unknown), (unknown), (unknown), Álex Bataller, Clara Maluquer, Dolors Colomer, Marı́a Rozman, Montserrat Arnán, Blanca Xicoy, Jordi Esteve, Marina Díaz‐Beyá	3
10	Real-World Data on Chronic Myelomonocytic Leukemia: Clinical and Molecular Characteristics, Treatment, Emerging Drugs, and Patient Outcomes 2022 ·Cancers ·(unknown), Mònica López‐Guerra, (unknown), Álex Bataller, (unknown), (unknown), Francesca Guijarro, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Sı́lvia Beà, Dolors Costa, Dolors Colomer, Marı́a Rozman, Jordi Esteve, Marina Díaz‐Beyá	9
11	Safety of COVID-19 vaccination in patients with clonal mast cell disorders 2022 ·The Journal of Allergy and Clinical Immunology In Practice ·(unknown), (unknown), Marina Díaz‐Beyá, Miguel Piris‐Villaespesa, (unknown), Rosa Muñoz‐Cano, David González‐de‐Olano	8
12	Allogeneic stem cell transplantation in AML with t(6;9)(p23;q34);DEK‐NUP214 shows a favourable outcome when performed in first complete remission 2020 ·British Journal of Haematology ·Marina Díaz‐Beyá, Myriam Labopin, Johan Maertens, (unknown), Jakob Passweg, Dietrich W. Beelen, Harry C. Schouten, Gérard Socié, Nicolaas Schaap, Rainer Schwerdtfeger, Liisa Volin, Mauricette Michallet, Emmanuelle Polge, Jorge Sierra, Mohamad Mohty, Jordi Esteve, Arnon Nagler, (unknown)	14
13	A 4-gene expression prognostic signature might guide post-remission therapy in patients with intermediate-risk cytogenetic acute myeloid leukemia 2018 ·Leukemia & lymphoma ·Montserrat Torrebadell, Marina Díaz‐Beyá, Susana G. Kalko, Marta Pratcorona, Josep Nomdedéu, Alfons Navarro, Bernat Gel, Salut Brunet, Jorge Sierra, Mireia Camós, Jordi Esteve	16
14	Inhibition of serotonin receptor type 1 in acute myeloid leukemia impairs leukemia stem cell functionality: a promising novel therapeutic target 2017 ·Leukemia ·(unknown), (unknown), (unknown), (unknown), Meritxell Nomdedéu, (unknown), Marta Pratcorona, Marina Díaz‐Beyá, Jordi Esteve, Ruth M. Risueño	15
15	Repositioning of bromocriptine for treatment of acute myeloid leukemia 2016 ·Journal of Translational Medicine ·(unknown), (unknown), (unknown), (unknown), (unknown), Meritxell Nomdedéu, Marina Díaz‐Beyá, Jordi Esteve, Ruth M. Risueño	19
16	MicroRNA expression at diagnosis adds relevant prognostic information to molecular categorization in patients with intermediate-risk cytogenetic acute myeloid leukemia 2013 ·Leukemia ·Marina Díaz‐Beyá, Salut Brunet, Josep Nomdedéu, Rut Tejero, Tania Díaz, Marta Pratcorona, Mar Tormo, Josep‐María Ribera, Lourdes Escoda, Rafael F. Duarte, David Gallardo, Inmaculada Heras, Maria Paz Queipo De Llano, Joan Bargay, Mariano Monzó, Jorge Sierra, Alfons Navarro, Jordi Esteve, (unknown)	47
17	MiR-SNPs as Markers of Toxicity and Clinical Outcome in Hodgkin Lymphoma Patients 2013 ·PLoS ONE ·Alfons Navarro, Carmen Muñoz, Anna Gayà, Marina Díaz‐Beyá, Bernat Gel, Rut Tejero, Tania Díaz, Antonio Martı́nez, Mariano Monzó	18
18	Efficacy of lenalidomide in a patient with myelodysplastic syndrome with isolated del(5q) and JAK2V617F mutation 2011 ·Leukemia Research ·Meritxell Nomdedéu, Margherita Maffioli, Xavier Calvo, Alejandra Martínez‐Trillos, Tycho Baumann, Marina Díaz‐Beyá, (unknown), Marı́a Rozman, Dolors Costa, Jordi Esteve, Francisco Cervantes, Dolors Colomer, Benet Nomdedeu	2
19	The Incidence of Veno-Occlusive Disease Following Allogeneic Hematopoietic Stem Cell Transplantation Has Diminished and the Outcome Improved over the Last Decade 2011 ·Biology of Blood and Marrow Transplantation ·Enric Carreras, Marina Díaz‐Beyá, Laura Rosiñol, Carmen Martı́nez, Francesc Fernández‐Avilés, Montserrat Rovira	132
20	Efficacy and tolerability of hydroxyurea in the treatment of the hyperproliferative manifestations of myelofibrosis: results in 40 patients 2010 ·Annals of Hematology ·Alejandra Martínez‐Trillos, Anna Gayà, Margherita Maffioli, Eduardo Arellano‐Rodrigo, Xavier Calvo, Marina Díaz‐Beyá, Francisco Cervantes	108

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact